Generation Impact Global announces launch of QB-EDGE: A smarter way to Collect, Collaborate, and Comply
2.9.2025 08:20:00 CEST | Business Wire | Press Release
Generation Impact Global (GIG), a Swiss RegTech company specialising in sustainability and non-financial data management, today announced the official launch of QB-EDGE, its next-generation questionnaire and data collection tool.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250901325433/en/
Built for financial institutions, corporates, and multi-stakeholder ecosystems, QB-EDGE addresses one of the most pressing challenges in ESG and regulatory reporting: how to collect and manage complex data across multiple teams and frameworks without chaos or inefficiency.
A tool designed for what matters most
QB-EDGE was created to address the core challenges organisations face in sustainability reporting:
- Collaboration. Real-time comments, structured review workflows, approval tracking, integrated audit logs, and evidence attachments bring teams together. Unlike competitor tools, QB-EDGE includes collaboration as a built-in capability.
- Customisation. Users can design questionnaires from scratch or adapt reusable templates, with support for varied question types (text, number, rating, image, and more). Template versioning, usage tracking, and icon selection make the tool flexible across sectors and geographies.
- Compliance. QB-EDGE natively supports universal frameworks. Results are exportable and integration-ready, with full audit traceability.
With these capabilities, QB-EDGE transforms ESG data collection into a structured, reliable process that supports both compliance requirements and business decision-making.
A step ahead of the market
“Most questionnaire tools stop at data capture. They don’t solve the bigger challenge of compliance, collaboration, and traceability,” said Anna Shpak, CEO of Generation Impact Global. “QB-EDGE is different. It was built not only to make data collection easier, but to give organisations peace of mind that they are compliant, audit-ready, and in control.”
With regulators, investors, and stakeholders demanding higher levels of accountability, QB-EDGE represents a timely solution for companies looking to strengthen both their sustainability reporting and their internal processes.
Availability
QB-EDGE is officially available from September 2, 2025. Organisations can request a demo or learn more at https://generationimpact.global/qb-edge/.
About Generation Impact Global
Generation Impact Global (GIG) is a Geneva,Switzerland based RegTech company specialising in non-financial data management and RegTech. Its solutions, including QB-EDGE, the GRI Sustainability Taxonomy, and UtilityIQ, are designed to help organisations collect, structure, and report non-financial data with the same rigour as financial information. GIG is committed to building tools that make impact data accessible, actionable, and accountable.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250901325433/en/
Contacts
Media Contact:
Anna Shpak,
Chief Executive Officer
Generation Impact Global SA
info@generationimpact.global
www.generationimpact.global -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.generationi
mpact.global&esheet=54316363&newsitemid=20250901325433&lan=en-US&anchor=www.gene
rationimpact.global&index=2&md5=f103031f7232e9ed9db9892994d9dff2
imagery QB-EDGE: link -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdrive.google.c
om%2Fdrive%2Ffolders%2F1xgx3RHokne5110hNcwPFsdPwzkhW2kHZ%3Fusp%3Ddrive_link&eshe
et=54316363&newsitemid=20250901325433&lan=en-US&anchor=link&index=3&md5=8ea65995
af294d30f6ff2d7256c718cd
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom